An2 therapeutics, inc.ANTX.US Overview

US StockHealthcare

(No presentation for ANTX)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ANTX Overall Performance

ANTX AI Analysis & Strategy

ANTX Recent Performance

-2.69%

An2 therapeutics, inc.

0.81%

Avg of Sector

-1.14%

S&P500

ANTX PowerScanner

ANTX Key Information

ANTX Valuation Metrics

ANTX Earnings Table

ANTX Profile

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.